Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

Roberto Ortiz,Edwin DeJesus,Homayoon Khanlou,Evgeniy Voronin,Jan van Lunzen,Jaime Andrade-Villanueva,Jan Fourie,Sandra De Meyer,Martine De Pauw,Eric Lefebvre,Tony Vangeneugden,Sabrina Spinosa-Guzman

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

2008

Roberto Ortiz
Edwin DeJesus
Homayoon Khanlou
Evgeniy Voronin
Jan van Lunzen
Jaime Andrade-Villanueva
Jan Fourie
Sandra De Meyer
Martine De Pauw
Eric Lefebvre
Tony Vangeneugden
Sabrina Spinosa-Guzman

Background:The present primary analysis of AntiRetroviral Therapy with TMC114 ExaMined In naive Subjects (ARTEMIS) compares the efficacy and safety of once-daily darunavir/ritonavir (DRV/r) with that of lopinavir/ritonavir (LPV/r) in treatment-naive patients.Methods:Patients with HIV-1 RNA at least

Keywords:

Virology
Immunology
Lopinavir/ritonavir
Ritonavir
Darunavir
Medicine
Lopinavir
Darunavir+Ritonavir
Viral disease
Lentivirus
Sida
Emtricitabine
Adverse effect
Confidence interval

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

345

Citations